Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury

Abstract

Traumatic brain injury (TBI) is a major cause of preventable death and morbidity in young adults. This complex condition is characterized by a significant blood-brain barrier leakage that stems from cerebral ischemia, inflammation, and redox imbalances in the traumatic penumbra of the injured brain. Recovery of function after TBI is partly through neuronal plasticity. In order to test whether combination therapy with melatonin and dexamethasone (DEX) might improve functional recovery, a controlled cortical impact (CCI) was performed in adult mice, acting as a model of TBI. Once trauma has occurred, combating these exacerbations is the keystone of an effective TBI therapy. The therapy with melatonin (10 mg/kg) and DEX (0.025 mg/kg) is able to reduce edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazolium chloride staining across the brain sections. Melatoninand DEX-mediated improvements in tissue histology shown by the reduction in lesion size and an improvement in apoptosis level further support the efficacy of combination therapy. The combination therapy also blocked the infiltration of astrocytes and reduced CCI-mediated oxidative stress. In addition, we have also clearly demonstrated that the combination therapy significantly ameliorated neurological scores. Taken together, our results clearly indicate that combination therapy with melatonin and DEX presents beneficial synergistic effects, and we consider it an avenue for further development of novel combination therapeutic agents in the treatment of TBI that are more effective than a single effector molecule.

The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-κB/Nuclear Transcription Factor Related to NF-E2

“…The rotarod treadmill (Accuscan, Inc., Columbus, OH) assesses motor balance and coordination. For testing, the animals were subjected to three trials; the average score was used as the individual rotarod score, as previously described (12).…”

Brain injury results in lower levels of melatonin receptors subtypes MT1 and MT2

“…Pre-clinical studies have found MEL leads to attenuation of one or more of the histopathological and functional consequences of TBI [13,14]. Moreover, published evidence suggests that MEL has many mechanisms of action, including anti-apoptotic [15,16], anti-oxidative [17], and anti-mitophagic [18] properties; notably, the abovementioned pathways are all well-established as implicated in TBI-pathology.…”

Comparative efficacy of melatonin in attenuation of endotoxin/LPS induced hepatotoxicity in BALB/c mice

“…unlike this study many studies have showed synergistic effect of dexamethasone and melatonin in various inflammatory disorders having somewhat same pathophysiology as in sepsis. 39,40 The discrepancy may be due to alteration in this methodology and pathophysiology of LPS induced hepatotoxicity. This study clearly demonstrates that both dexamethasone and melatonin restored LPS induced liver injury in this animal model.…”